Abstract
CDC has issued guidelines on the evaluation of persons with a history of exposure to Bacillus anthracis spores or who have an occupational or environmental risk for anthrax exposure. This notice describes the clinical evaluation of persons who are not known to be at increased risk for anthrax but who have symptoms of influenza-like illness (ILI). Clinicians evaluating persons with ILI should consider a combination of epidemiologic, clinical, and, if indicated, laboratory and radiographic test results to evaluate the likelihood that inhalational anthrax is the basis for ILI symptoms.
Highlights
CDC AND STATE AND LOCAL PUBLIC health authorities continue to investigate cases of bioterrorism-related anthrax
As of November 7, a total of 22 cases of anthrax have been identified according to the CDC surveillance case definition; 10 were confirmed inhalational anthrax cases and 12 cases were cutaneous anthrax (Table 1)
The District of Columbia (DC) in which letters contaminated with anthrax were handled or processed using highspeed sorting machines, or at media companies in New York City (NYC) or Florida (FL) where letters, either confirmed or presumed to be contaminated with anthrax, were opened or handled
Summary
CDC AND STATE AND LOCAL PUBLIC health authorities continue to investigate cases of bioterrorism-related anthrax. The probable exposures for a case of cutaneous anthrax in NJ and a case of inhalational anthrax in NYC remain unknown Epidemiologic investigations of these cases and surveillance to detect new cases of bioterrorismassociated anthrax continue. Since the last report,[1] one additional case of confirmed cutaneous anthrax has been identified in a 38-year-old man who worked at a media company in NYC. This is the third case of cutaneous anthrax reported among employees at the media company and is probably associated with a contaminated letter postmarked Sep2536 tember 18 that was handled during October 12-15. Clean-up at contaminated sites and surveillance for new anthrax cases are ongoing
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
